Padeliporfin VTP Treatment for Unresectable Pancreatic Adenocarcinoma

Impact Biotech

Status and phase: Enrolling; Phase 1

Conditions: Locally Advanced Unresectable Pancreatic Adenocarcinoma

Treatments: Combination Product: Padeliporfin Vascular Targeted Photodynamic (VTP) therapy

Study type: Interventional

Funder types: Industry; Other

Identifiers

NCT05919238

CLIN2301 PNCM101

Details and patient eligibility

About

This is a prospective, multicenter, non-randomized, open label light dose escalation phase I trial to evaluate the safety and preliminary efficacy of Padeliporfin vascular targeted photodynamic therapy (VTP) applied via endovascular fiber placement within a dilatation catheter, through the superior mesenteric artery (SMA) in patients with stage III, locally advanced (LA) unresectable pancreatic ductal adenocarcinoma (PDAC). The investigators will evaluate safety and preliminary efficacy of Padeliporfin VTP administered endovascularly using light dose escalation.

Full description

This is a prospective, multicenter, non-randomized, open label light dose escalation phase I trial to evaluate the safety and preliminary efficacy of Padeliporfin vascular targeted photodynamic therapy (VTP) applied via endovascular fiber placement within a dilatation catheter, through the superior mesenteric artery (SMA) in patients with stage III, locally advanced (LA) unresectable pancreatic ductal adenocarcinoma (PDAC) with SMA solid tumor encasement >180°. The investigators will evaluate safety and preliminary efficacy of Padeliporfin VTP administered endovascularly using light dose escalation.

Study Intervention: Patients enrolled in the study will undergo endovascular VTP, using Padeliporfin (WST-11) activated via endovascular fiber placement through the SMA, with intravenous administration of Padeliporfin at a fixed dose of 4 mg/kg of padeliporfin di-potassium, followed by total of 10 min illumination at 753 nm.

For light dose escalation (Part A), a 3+3 dose-escalation schema will be used. In a subsequent expansion phase (Part B), the optimal light dose as per light dose escalation, will be used in an additional cohort of patients to further evaluate preliminary efficacy.

Enrollment: 30 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Patients 18 years of age and older
2. Capable of giving written informed consent
3. Patients with a diagnosis of Stage III pancreatic ductal adenocarcinoma, cytologically or histologically confirmed per American Joint Committee on Cancer (AJCC) staging criteria
4. Patient has a unresectable tumor, evaluated as Stage III according to National Comprehensive Cancer Network (NCCN) guidelines resectability criteria, based on radiographic imaging or exploratory surgery as a locally advanced (LA) pancreatic ductal adenocarcinoma (PDAC)
5. Patients with LA PDAC located in the head/uncinate process of the pancreas, with SMA encasement ˃180° for a total proximal SMA encasement length up to 3cm
6. Measurable disease as defined by the Response Evaluation Criteria in Solid Tumors according to RECIST 1.1
7. ECOG performance status </= 1
8. Life expectancy at least 3 months
9. No evidence of metastatic disease by CT scan chest abdomen and pelvis performed within 14 days prior to treatment
10. Adequate Hematological, biochemical, and organ (kidney, liver, cardiac) function
11. International normalized ratio (INR) <1.5 unless the patient is receiving anticoagulation therapy, in which case a therapeutic INR is acceptable. Anticoagulation therapy with low-molecular-weight heparin or warfarin, whether medically indicated, is permitted.
12. May have received prior neoadjuvant systemic therapy
13. No prior external beam radiation therapy to the pancreas
14. No comorbidities which would preclude access to the superior mesenteric artery by intravascular catheterization

Exclusion criteria

1. Metastatic (stage IV) disease (including involvement of the colon, adrenals, or kidney, or radiographic evidence of peritoneal seeding or pulmonary metastases)
2. SMA anatomical variants (SMA origin not from aorta)
3. Previous radiotherapy treatment for pancreatic cancer
4. Cystic component >= 25% the total volume of the tumor
5. Ascites detected by CT, ultrasound (US) or MRI;
6. Diagnosis of islet cell tumor, lymphoma, metastatic lesion, acinar cell (or other atypical pathologic malignancy)
7. History of other malignancy requiring treatment in the past 2 years
8. Unable to receive or previously intolerant of moderate and/or deep sedation
9. Any other medical or social condition deemed by the investigator to be likely to interfere with a subject's ability to sign informed consent, cooperate, and participate in the study or that is likely to interfere with the interpretation of the results
10. Pregnant and/or nursing
11. Active infection, with the exception of resolving cholangitis
12. Known hypersensitivity to iodine contrast
13. Receipt of concurrent investigational therapy or within 30 days of protocol initiation
14. Any other medical or psychiatric comorbidities, including decompensated heart failure, unstable angina or coronary artery disease or severe pulmonary disease, that, in the opinion of the study investigator, would make the patient a poor candidate for the study
15. Systemic chemotherapy treatment within less than 30 days prior to planned VTP or/and for VEGF-targeted therapy within less than 2 months prior to planned VTP treatment
16. Prohibited medication that could not be adjusted or discontinued prior to study treatment
17. Patients with photosensitive skin diseases or porphyria

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Sequential Assignment

Masking: None (Open label)

---

30 participants in 2 patient groups

Part A

Experimental group

Description:

will be a monotherapy light dose escalation with single dose of Padeliporfin at light laser doses of 200, 400 and 600 mW/cm for 10 minutes. Part A will proceed with light dose escalation and will continue until the maximum tolerated light dose (MTD) and/or recommended phase 2 dose (RP2D) is defined.

Treatment:

Combination Product: Padeliporfin Vascular Targeted Photodynamic (VTP) therapy

Part B

Experimental group

Description:

will be a dose expansion part at MTD/RP2D dose level identified in Part A to further assess the safety, tolerability, and treatment effect of the MTD and/ or RP2D

Treatment:

Combination Product: Padeliporfin Vascular Targeted Photodynamic (VTP) therapy